A healthcare provider will administer Treanda at a hospital or other healthcare setting over a 30- to 60-minute period. It is given as a slow injection into a vein once a day for two days in a row every 21 to 28 days. The dosage of Treanda your healthcare provider recommends will depend on the reason you are using it and other factors.
The dose of Treanda® (bendamustine) your healthcare provider recommends will vary, based on a number of factors, including:
- Your height and weight
- The reason you are using it
- How you respond to the medication.
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
The recommended Treanda dose for the treatment of chronic lymphocytic leukemia (CLL) is based on body surface area, which is normally calculated using height and weight. Dosing based on body surface area is expressed as milligrams per meters squared (mg per m2).
Specifically, the recommended dose is 100 mg per m2 given intravenously (by IV) over 30 minutes. This dose is given once a day for two days in a row every 28 days. This 28-day period is called a treatment cycle. Treanda is given on days one and two of the cycle, followed by 26 days without treatment. The cycle may then be repeated up to six times.
Your healthcare provider may reduce your amount or recommend a longer break between doses if you experience potentially serious Treanda side effects, such as low blood cell counts. For example, some people with CLL may be given doses as low as 25 mg per m2.